Gibbs Wealth Management boosted its position in Novo Nordisk A/S (NYSE:NVO – Free Report) by 115.7% in the 1st quarter, Holdings Channel reports. The fund owned 39,273 shares of the company’s stock after purchasing an additional 21,065 shares during the period. Gibbs Wealth Management’s holdings in Novo Nordisk A/S were worth $1,443,000 at the end of the most recent quarter.
Several other institutional investors also recently bought and sold shares of the business. Quotient Wealth Partners LLC grew its holdings in Novo Nordisk A/S by 2.0% in the 4th quarter. Quotient Wealth Partners LLC now owns 9,091 shares of the company’s stock valued at $463,000 after buying an additional 177 shares during the period. Certuity LLC increased its stake in shares of Novo Nordisk A/S by 3.6% during the 4th quarter. Certuity LLC now owns 5,052 shares of the company’s stock valued at $257,000 after acquiring an additional 177 shares during the last quarter. Oakworth Capital Inc. lifted its holdings in shares of Novo Nordisk A/S by 41.6% during the 4th quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock worth $31,000 after acquiring an additional 182 shares during the period. True North Advisors LLC boosted its position in shares of Novo Nordisk A/S by 3.9% in the fourth quarter. True North Advisors LLC now owns 5,305 shares of the company’s stock worth $270,000 after acquiring an additional 199 shares during the last quarter. Finally, Asio Capital LLC boosted its position in shares of Novo Nordisk A/S by 3.9% in the fourth quarter. Asio Capital LLC now owns 5,386 shares of the company’s stock worth $274,000 after acquiring an additional 200 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.
Novo Nordisk A/S Trading Down 0.0%
NYSE NVO opened at $48.18 on Friday. The firm has a market capitalization of $215.12 billion, a price-to-earnings ratio of 11.31, a PEG ratio of 4.39 and a beta of 0.77. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $71.79. The company’s 50 day moving average price is $46.28 and its 200 day moving average price is $45.72.
Analyst Upgrades and Downgrades
Several brokerages recently commented on NVO. Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday. Wolfe Research initiated coverage on shares of Novo Nordisk A/S in a research note on Thursday, March 26th. They set a “peer perform” rating for the company. Weiss Ratings restated a “sell (d+)” rating on shares of Novo Nordisk A/S in a report on Monday. Finally, Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Five research analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $65.56.
Get Our Latest Stock Analysis on Novo Nordisk A/S
Novo Nordisk A/S Profile
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.
The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.
Featured Stories
- Five stocks we like better than Novo Nordisk A/S
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
- Alphabet Crushed Earnings, But One Number Spooked the Market
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.
